loading
Schlusskurs vom Vortag:
$87.82
Offen:
$87.82
24-Stunden-Volumen:
59,677
Relative Volume:
0.08
Marktkapitalisierung:
$5.55B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-31.08
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
-4.40%
1M Leistung:
+40.70%
6M Leistung:
+49.51%
1J Leistung:
+75.54%
1-Tages-Spanne:
Value
$86.86
$89.25
1-Wochen-Bereich:
Value
$86.86
$92.08
52-Wochen-Spanne:
Value
$40.61
$94.80

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Firmenname
Rhythm Pharmaceuticals Inc
Name
Telefon
857-264-4280
Name
Adresse
222 BERKELEY STREET, BOSTON, MA
Name
Mitarbeiter
283
Name
Twitter
@rhythmpharma
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
RYTM's Discussions on Twitter

Vergleichen Sie RYTM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
87.18 5.90B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.48 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.50 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.06 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
573.01 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.35 29.19B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Eingeleitet Goldman Buy
2025-07-07 Eingeleitet Leerink Partners Outperform
2025-04-07 Hochstufung BofA Securities Neutral → Buy
2025-03-05 Fortgesetzt Stifel Buy
2025-01-02 Eingeleitet Jefferies Buy
2024-12-20 Eingeleitet Oppenheimer Outperform
2024-10-21 Eingeleitet Guggenheim Buy
2024-09-18 Eingeleitet H.C. Wainwright Buy
2024-09-17 Eingeleitet JMP Securities Mkt Outperform
2024-05-08 Herabstufung BofA Securities Buy → Neutral
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-08-01 Hochstufung BofA Securities Neutral → Buy
2023-01-18 Fortgesetzt Canaccord Genuity Buy
2022-08-08 Hochstufung Goldman Neutral → Buy
2022-08-05 Hochstufung BofA Securities Underperform → Neutral
2022-06-17 Bestätigt Needham Buy
2022-03-02 Fortgesetzt Stifel Buy
2022-02-17 Hochstufung Ladenburg Thalmann Neutral → Buy
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-14 Fortgesetzt Goldman Neutral
2021-08-04 Herabstufung BofA Securities Neutral → Underperform
2021-08-04 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-11-30 Herabstufung BofA Securities Buy → Neutral
2020-01-08 Eingeleitet Goldman Sell
2019-07-12 Hochstufung Stifel Hold → Buy
2019-07-08 Eingeleitet Canaccord Genuity Buy
2019-03-13 Eingeleitet Ladenburg Thalmann Buy
2018-09-07 Fortgesetzt Morgan Stanley Overweight
2018-06-25 Bestätigt Needham Buy
2018-06-15 Bestätigt Needham Buy
2017-10-30 Eingeleitet BofA/Merrill Buy
2017-10-30 Eingeleitet Needham Buy
Alle ansehen

Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Rhythm Pharmaceuticals Inc. a good long term investmentRapid growth trajectories - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastDynamic profit expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Rhythm Pharmaceuticals Inc. stock priceConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Should You Invest in This Under-the-Radar Weight Loss Stock? - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

Rhythm Pharmaceuticals prices $175M stock offering - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

(RYTM) Investment Analysis - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 15, 2025

Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada

Jul 15, 2025
pulisher
Jul 13, 2025

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals announces public offering of common stock - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN

Jul 12, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Explores New Treatment for Hypotha - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals' Bivamelagon: A Path to Dominating Acquired Hypothalamic Obesity and Driving Stock Gains - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Gets Price Target Boost from Oppen - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals prices upsized public offering at $85 per share - Investing.com India

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by B of A Secu - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110 By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Guggenheim Raises Rhythm Pharmaceuticals (RYTM) Price Target Ami - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33% - simplywall.st

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Shares Slide Following Stock Offering - GuruFocus

Jul 10, 2025

Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Smith Hunter C
Chief Financial Officer
Jul 09 '25
Sale
80.48
42,120
3,389,756
116,915
Shulman Joseph
Chief Technical Officer
Jul 09 '25
Option Exercise
6.80
7,969
54,189
16,478
Shulman Joseph
Chief Technical Officer
Jul 09 '25
Sale
77.78
7,969
619,851
8,509
German Christopher Paul
Corporate Controller & CAO
Jul 09 '25
Option Exercise
27.29
2,850
77,786
4,739
German Christopher Paul
Corporate Controller & CAO
Jul 09 '25
Sale
80.75
3,817
308,217
922
Cramer Pamela J.
Chief Human Resources Officer
Jul 09 '25
Option Exercise
13.43
15,572
209,153
34,781
Cramer Pamela J.
Chief Human Resources Officer
Jul 09 '25
Sale
77.13
15,572
1,201,062
19,209
$22.84
price up icon 4.79%
$36.02
price down icon 0.12%
$102.58
price down icon 0.21%
$27.91
price up icon 5.14%
$113.56
price up icon 1.86%
biotechnology ONC
$295.56
price down icon 0.03%
Kapitalisierung:     |  Volumen (24h):